JUNS · Jupiter Neurosciences, Inc.
$0.12
-0.03 (-20.39%)
At close · Jul 24
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In management's opinion, these conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of at least twelve months from the date of this report.”View the 10-Q filed May 14, 2026
Market Cap
$4.39M
Shares
36.28M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$21.8K
FY2025
Net Income
-$8.64M
-254.4%
FY2025
Gross Margin
80.59%
FY2025
Operating Margin
-40873.19%
FY2025
Diluted EPS
-$0.25
-212.5%
FY2025
Operating Cash Flow
-$5.41M
-38.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| — | $21.8K | $0 | — | |
| — | $4231 | — | — | |
| — | $17.57K | — | — | |
| — | 80.59% | — | — | |
| $2.03M | $2.09M | $492.66K | $954.79K | |
| $7.33M | $6.84M | $2.6M | $2.92M | |
| — | $6.84M | — | — | |
| $9.37M | $8.93M | $3.09M | $3.87M | |
| -$9.33M | -$8.91M | -$3.09M | -$3.87M | |
| — | -40873.19% | — | — | |
| $183.44K | $66.02K | $248.37K | $218.71K | |
| — | — | $5557 | $482 | |
| $155.73K | $263.82K | $651.66K | -$912.92K | |
| -$9.18M | -$8.64M | -$2.44M | -$4.78M | |
| — | -39662.77% | — | — | |
| USD/shares | — | -$0.25 | -$0.08 | -$0.18 |
| USD/shares | — | -$0.25 | -$0.08 | -$0.18 |
| shares | — | 34.63M | 28.78M | 26.41M |
| shares | — | 34.63M | 28.78M | 26.41M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.07×